Healthcare
Live Price
Offline$1.64
+8.61% today
1Y Change
+99.47%
Window
Jun 27, 2025 → Jun 18, 2026
Coverage: 245 bars · Jun 27, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neumora Therapeutics, Inc. Common Stock (NMRA) is a Healthcare stock with a market cap of $450.00M and listed on NASDAQ. The stock last traded around $1.64 and up 99.5% across the available one-year price window (Jun 27, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +5.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +5.2%, free cash flow -12.8% with operating margin 0.0% and ROIC -151.8%. Stock Foundry combines NMRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NMRA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NMRA Max Drawdown
-74.51%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NMRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$237.3M
-81.3% YoY
Free Cash Flow
-$76.2M
+33.9% YoY
Revenue Growth
+0.0%
EPS Growth
+5.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -5M | 0 | -668K | 0 | 0 |
| Operating Income | -241M | -263M | -188M | -136M | -237M |
| EBITDA | -233M | -263M | -188M | -135M | -237M |
| Net Income | -237M | -244M | -236M | -131M | -237M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 183M | 142M | 374M | 241M | 409M |
| Total Assets | 191M | 317M | 496M | 426M | 429M |
| Total Liabilities | 87M | 30M | 27M | 873M | 755M |
| Shareholder Equity | 104M | 287M | 469M | -447M | -325M |
| Total Debt | 477K | 2M | 5M | 8M | 2M |
| Net Debt | -182M | -140M | -369M | -233M | -407M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
75M
+34.4% YoY
Capital Expenditures
817K
-59.9% YoY
Free Cash Flow
76M
+33.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-146.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.